Methods are described for increasing levels of healthy vaginal bacteria by treating the vaginal mucosa with bacteriocins derived from Lactobacillus paragasseri, Lactobacillus gasseri, and other bacterial strains. The bacteriocins are surprisingly advantageous as being selectively active against Lactobacillus iners but relatively inactive against H.sub.2O.sub.2-producing Lactobacillus species. Because L. iners is involved in the onset and maintenance of vaginal dysbiosis, selective removal of this bacterium from the vaginal microbiome treats or prevents conditions associated with vaginal dysbiosis, such as bacterial vaginosis and its sequelae.

A method of treating an infection of a lung in a patient in need thereof according to an embodiment includes administering to the patient an effective amount of a compound having the formula:

##STR00001##

or a pharmaceutically acceptable salt thereof.

A method of treating an infection of a lung in a patient in need thereof according to an embodiment includes administering to the patient an effective amount of a compound having the formula:

##STR00001##

or a pharmaceutically acceptable salt thereof.

The present invention describes a new method for the prevention or treatment of molar pregnancies, more particularly familial recurrent hydatidiform mole, and more particularly hydatidiform mole diseases caused by a mutation in the NLRP7 gene.

The present invention describes a new method for the prevention or treatment of molar pregnancies, more particularly familial recurrent hydatidiform mole, and more particularly hydatidiform mole diseases caused by a mutation in the NLRP7 gene.

Described herein are methods of reducing the risk of recurrence of bacterial vaginosis by intravaginal administration of compositions comprising L-lactic acid, polymer thickener, and preservative.

Described herein are methods of reducing the risk of recurrence of bacterial vaginosis by intravaginal administration of compositions comprising L-lactic acid, polymer thickener, and preservative.

The present invention relates to a composition comprising as active ingredients an extract of Cetraria islandica, silver and/or a salt thereof and hyaluronic acid and/or a salt thereof. The present invention further relates to the use of such composition for the treatment of skin and/or mucous membrane diseases.

A formulation for vaginal administration comprising an effective amount of a composition of dried Lactobacillus cells and boric acid, with a carrier. The composition can include one or more antioxidants. Optionally, the composition is in a unit dosage form. Also provided are methods for making and using the composition.

Method of treating sexually transmitted infection in a subject in need thereof involving administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a volume-weighted particle size distribution within a microgranule population, wherein the volume-weighted particle size distribution as measured from a representative sample of the microgranule population comprises (a) 10% of the microgranule population having a volume-weighted particle size about no less than 470 micrometers; (b) 50% of the microgranule population having a volume-weighted particle size between about no less than 640 micrometers and about no more than 810 micrometers; (c) 90% of the microgranule population having a volume-weighted particle size about no more than 1170 micrometers; or (d) a combination thereof, which can include some or all of (a) through (c) above. Pharmaceutical compositions and uses thereof are included herein.